Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy

American Journal of Hematology

Volumn 87, Issue 8, 2012, Pages 749-753

  Bibas, Michele ^a   Trotta, Maria Paola ^a   Cozzi Lepri, Alessandro ^b,c   Lorenzini, Patrizia ^a   Pinnetti, Carmela ^a   Rizzardini, Giuliano ^d   Angarano, Gioacchino ^e   Caramello, Pietro ^f   Sighinolfi, Laura ^f   Mastroianni, Claudio Maria ^g   Mazzarello, Giovanni ^h   Di Caro, Antonino ^a   Di Giacomo, Cristina ^a   d'Arminio Monforte, Antonella ⁱ   Antinori, Andrea ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f Department of Infectious Diseases ^*  (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

^h UNIVERSITY OF GENOA   (Italy)

ⁱ UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN;

ADULT; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; ITALY; MALE; NONHODGKIN LYMPHOMA; PREDICTOR VARIABLE; PRIORITY JOURNAL; VIREMIA;

ADULT; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RISK FACTORS;

EID: 84863991530     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23236     Document Type: Article

References (34)

1. Grulich AE, van Leeuwen MT, Falster MO, Vajdic CM. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: A meta-analysis: Lancet 2007; 370: 59-67.
2. Simard EP, Engels EA. Cancer as a cause of death among people with AIDS in the United States. Clin Infect Dis 2010; 51: 957-962.
3. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immnunodeficiency virus infected adults. J Natl Cancer Inst 2000; 92: 1823-1830.
4. Simard EP, Pfeiffer RM, Engels EA. Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2011; 117: 1089-1096.
5. Bohlius J, Schmidlin K, Boué F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: Incidence and evolution of CD4+ T-cell lymphocytes. Blood 2011; 117: 6100-6108.
6. Clifford GM, Rickenbach M, Lise M, et al. Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009; 113: 5737-5742.
7. Stebbing J, Gazzard B, Mandalia S, et al. Antiretroviral treatment regimens and immune parameters in the prevention of systemic AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 2004; 22: 2177-2183.
8. Engels EA, Pfeiffer RM, Landgren O, Moore RD. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J Acquir Immune Defic Syndr 2010; 54: 78-84.
9. Cagigi A, Nilsson A, De Milito A, Chiodi F. B cell immunopathology during HIV-1 infection: Lesson to learn for HIV-1 vaccine design. Vaccine 2008; 26: 3016-3025.
10. Moir S, Buckner CM, Ho J, et al. B cells in early and chronic HIV infection: Evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010; 116: 5571-5579.
11. Vendrame E, Martínez-Maza O. Assessment of pre-diagnosis biomarkers of immune activation and inflammation: Insights on the etiology of lymphoma. J. Proteome Res 2011; 10: 113-119.
12. Breen EC, Fatahi S, Epeldegui M, Boscardin WJ, Detels R, Martínez-Maza O. Elevated serum soluble CD30 precedes the development of AIDS-associated non-Hodgkin's B cell lymphoma. Tumour Biol 2006; 27: 187-194.
13. Landgren O, Goedert JJ, Rabkin CS, et al. Circulating serum free light chains as predictive markers of AIDS-related lymphoma. J Clin Oncol 2010; 28: 773-779.
14. Maurer MJ, Micaleff IN, Cerhan JA, et al. Elevated serum free light chains are associated with event-free and overall survival in two indipendent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol 2011; 29: 1620-1626.
15. Thompson CA, Maurer MJ, Cerhan JR, et al. Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. Am J Hematol 2011; 86: 998-1000.
16. Morabito F, De Filippi R, Laurenti L, et al. The cumulative amount of serum free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood 2011; 118: 6353-6361.
17. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. AIDS 2000; 14: 499-507.
18. Prosperi MC, Cozzi-Lepri A, Castagna A, et al. Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: Evidence from a large Italian cohort study. Clin Infect Dis 2010; 50: 1316-1321.
19. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification of prediction: Standards for study design. J Natl Cancer Inst 2008; 100: 1432-1438.
20. Hanash SM, Baik CS, Kallioniemi O. Emerging molecucal biomarkers-blood based strategies to detect and monitor cancer. Nat Rev Clin Oncol 2011; 8142-8150.
21. Katzmann JA, Clarck RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains. Clin Chem 2002; 48: 1437-1444.
22. Bradwell AR. Immunoglobuliln free light chains and their analysis: Normal ranges and reference interval. In: Serum Free Light Chain Analysis (plus Hevylite), 6th ed. University of Birmingham: The Binding Site Group; 2010; 36-42.
23. Hosmer DW, Lemeshow S. Applied Logistic Regression, 2nd ed.; John Wiley & Sons, Inc, 2000.
24. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73: 13-22.
25. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS 2000; 14: 133-140.
26. Gottenberg JE, Aucouturier F, Goetz J, et al: Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjogren's syndrome. Ann Rheum Dis 2007; 66: 23-27.
27. Diamantidis MD, Ioannidou-papagiannaki E, Ntaios G: Novel extended reference range for serum kappa/lamda free light chain ratio in diagnosing monoclonal gammopathies in renal insufficient patients. Clin Biochem 2009; 42: 1202-1203.
28. Hammer SM, Eron JJJr, Reiss P, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008; 300: 555-570.
29. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360: 1815-1826.
30. Bower M, Fisher M, Hill T, et al. CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica 2009; 94: 875-880.
31. Bibas M, Antinori A. EBV and HIV-related lymphoma. Mediterr J Hematol Infect Dis 2009; 1: e2009032.
32. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in person with HIV/AIDS. Blood 2006; 108: 3786-3791.
33. Bohlius J, Schmidlin K, Boué F, et al. HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: Incidence and evolution of CD4+ T-cell lymphocytes. Blood 2011; 117: 6100-6108.
34. Ayoub JP, Palmer JL, Huh Y, et al. Therapeutic and prognostic implications of peripheral blood lymphopenia in patients with Hodgkin's disease. Leuk lymphoma 1999; 34: 519-527.